MSD’s Keytruda and Padcev combination receives EC approval

The EC has approved MSD Keytruda plus Padcev as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults. The authorisation covers Iceland, Liechtenstein, Norway, and all 27 EU member states. The EC assessment was based on the Phase III KEYNOTE-B15 study, conducted alongside Astellas and Pfizer. Credit: PeopleImages / Shutterstock.com. The European Commission (EC) has approved Merck & Co’s (MSD) Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults. The clearance permits the therapies to be administered before radical cystectomy as neoadjuvant therapy and continued following surgery as adjuvant treatment. LOA…

Salong Debbarma · 2026-10-22

The EC has approved MSD Keytruda plus Padcev as perioperative treatment for resectable muscle-invasive bladder cancer (MIBC) in adults.

Source: Pharmaceutical Technology